Effectiveness of the Information Technology-Aided Program of Relapse Prevention in Schizophrenia (ITAREPS): A Randomized, Controlled, Double-Blind Study

被引:58
|
作者
Spaniel, Filip [1 ]
Hrdlicka, Jan [2 ]
Novak, Tomas [1 ]
Kozeny, Jiri [1 ]
Hoeschl, Cyril [1 ]
Mohr, Pavel [1 ]
Motlova, Lucie Bankovska [1 ]
机构
[1] Charles Univ Prague, Fac Med 3, Prague Psychiat Ctr, Ctr Neuropsychiat Studies, Prague 18103 8, Czech Republic
[2] Czech Tech Univ, Fac Elect Engn, Dept Cybernet, CR-16635 Prague, Czech Republic
关键词
schizophrenia; psychotic disorders; relapse prevention; hospitalizations; antipsychotic medication; information technology; FOLLOW-UP; THERAPY; PREDICTION; SYMPTOMS; EPISODE; COSTS; SIGNS;
D O I
10.1097/01.pra.0000416017.45591.c1
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Purpose. To evaluate the effectiveness of the Information Technology-Aided Program of Re lapse Prevention in Schizophrenia (ITAREPS). Methods. Relapse-prone outpatients with schizophrenia or schizoaffective disorder were randomized to the active (n = 75) or control group (n = 71). In the active arm, according to the protocol, investigators were prompted to increase the antipsychotic dose upon occurrence of a pharmacological intervention requiring event (PIRE) detected by ITAREPS. Results. Intention-to-treat (ITT) analysis found no between-group difference in the hospitalization-free survival rate at 12 months. However, the trial suffered from high non-adherence of investigators in the active group, with no antipsychotic dose increase in 61% of PIREs. Furthermore, Cox regression analysis showed a 11-fold increased risk of hospitalization in the absence of pharmacological intervention following a PIRE (hazard ratio [HR] = 10.8; 95% confidence interval [CI] 1.4-80.0; p = 0.002). Therefore, a post-hoc as-treated analysis was performed, which demonstrated a nine-fold reduction in the risk of hospitalization in ITAREPS Algorithm-Adherers (IAAs, n = 25) compared with the ITAREPS Non-interventional group (INIs, n = 70; Kaplan-Meier survival analysis, HR = 0.11, 95% CI 0.05-0.28, p = 0.009; number needed to treat [NNT] = 4, 95% CI 3-10). A significant difference in favor of the IAA group was seen in the number of inpatient days (p < 0.05) and costs (p < 0.05). Conclusion. Future ITAREPS trials should target the underlying mechanisms that cause low investigator adherence to the program. Trial registration: Clinical Trials NCT00712660 (Journal of Psychiatric Practice 2012; 18: 269-280)
引用
收藏
页码:269 / 280
页数:12
相关论文
共 50 条
  • [41] A Randomized, Double-Blind, Placebo-Controlled Trial of Fluvoxamine in Patients With Schizophrenia A Preliminary Study
    Niitsu, Tomihisa
    Fujisaki, Mihisa
    Shiina, Akihiro
    Yoshida, Taisuke
    Hasegawa, Tadashi
    Kanahara, Nobuhisa
    Hashimoto, Tasuku
    Shiraishi, Tetsuya
    Fukami, Goro
    Nakazato, Michiko
    Shirayama, Yukihiko
    Hashimoto, Kenji
    Iyo, Masaomi
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2012, 32 (05) : 593 - 601
  • [42] Lofexidine in Combination with Oral Naltrexone for Opioid Use Disorder Relapse Prevention: A pilot Randomized, Double-Blind, Placebo-Controlled Study
    Hermes, Gretchen
    Hyman, Scott M.
    Fogelman, Nia
    Kosten, Thomas R.
    Sinha, Rajita
    AMERICAN JOURNAL ON ADDICTIONS, 2019, 28 (06): : 480 - 488
  • [43] Lurasidone in the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo- and Olanzapine-Controlled Study
    Meltzer, Herbert Y.
    Cucchiaro, Josephine
    Silva, Robert
    Ogasa, Masaaki
    Phillips, Debra
    Xu, Jane
    Kalali, Amir H.
    Schweizer, Edward
    Pikalov, Andrei
    Loebel, Antony
    AMERICAN JOURNAL OF PSYCHIATRY, 2011, 168 (09): : 957 - 967
  • [44] A double-blind, placebo-controlled study of the effectiveness and safety of nizatidine in the prevention of postprandial heartburn
    Spiegel, JE
    Thoden, WR
    Pappas, K
    Fratarcangelo, P
    Furey, SA
    ARCHIVES OF INTERNAL MEDICINE, 1997, 157 (14) : 1594 - 1599
  • [45] Relapse prevention in adults with major depressive disorder treated with vilazodone: a randomized, double-blind, placebo-controlled trial
    Durgam, Suresh
    Gommoll, Carl
    Migliore, Raffaele
    Chen, Changzheng
    Chang, Cheng-Tao
    Aguirre, Michelle
    Thase, Michael E.
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2018, 33 (06) : 304 - 311
  • [46] A RANDOMIZED DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL OF PREGNENOLONE FOR NEGATIVE SYMPTOMS IN SCHIZOPHRENIA
    Savitz, Adam J.
    Silverstein, Steven
    Rasul, Rehana
    Sharma, Madhulika
    McGovern, Kelly
    English, Judith
    Siegel, Deborah
    Kim, Jason
    SCHIZOPHRENIA BULLETIN, 2015, 41 : S331 - S332
  • [47] Study on the effectiveness and safety of ciprofol in anesthesia in gynecological day surgery: a randomized double-blind controlled study
    Man, Yan
    Xiao, Hongyi
    Zhu, Teng
    Ji, Fanceng
    BMC ANESTHESIOLOGY, 2023, 23 (01)
  • [48] The effectiveness of intramuscular biperiden in acute akathisia - A double-blind, randomized, placebo-controlled study
    Baskak, Bora
    Atbasoglu, E. Cem
    Ozguven, Halise Devrimci
    Saka, Meram Can
    Gogus, Ali Kemal
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2007, 27 (03) : 289 - 294
  • [49] Study on the effectiveness and safety of ciprofol in anesthesia in gynecological day surgery: a randomized double-blind controlled study
    Yan Man
    Hongyi Xiao
    Teng Zhu
    Fanceng Ji
    BMC Anesthesiology, 23
  • [50] The effectiveness of trigger point treatment in rotator cuff pathology: A randomized controlled double-blind study
    Akbaba, Yildiz Analay
    Mutlu, Ebru Kaya
    Altun, Suleyman
    Turkmen, Ezgi
    Birinci, Tansu
    Celik, Derya
    JOURNAL OF BACK AND MUSCULOSKELETAL REHABILITATION, 2019, 32 (03) : 519 - 527